- Expansion doubles manufacturing capacity
- New assay development facilities
- New suite of services includes immunoassay development
Oxford, UK, 2nd May 2017: The Native Antigen Company (NAC) announced today that it has relocated into larger facilities, in Oxfordshire, UK. The new building has purpose-built laboratories and doubles the Company’s manufacturing capacity. This will increase the speed of new product development within NAC’s core business of infectious disease antigens and antibodies. The new laboratory space also enables NAC to add custom immunoassays to its offering to support customer’s ELISA assay and lateral flow device requirements.
The new suite of laboratories has been established to satisfy increasing commercial demands and accommodate NAC’s growing R&D pipeline. The move facilitates the expansion of the Company’s custom services for recombinant protein production, based on its proprietary mammalian cell expression system. The HEK293 expression system used at NAC has been used to prepare a wide range of complex recombinant proteins, that have been shown to be glycosylated and to demonstrate functional activity.
Dr Nick Roesen, Chief Scientific Officer, NAC, said: “I am delighted with the new facilities and the increased capacity that they provide. The addition of immunoassay development services will enable our customers to work with us from protein expression through to development of an immunoassay for a specific protein. In providing this new service we aim to fill the gap between small-scale R&D expression and high-end pharmaceutical scale GMP manufacturing. We are excited to offer this to our customers, while at the same time progressing our own new product pipeline for infectious disease antigens and anitbodies.”
For further information please contact:
Lorna Cuddon
Tel: +44 (0)7811 996 942
lorna.cuddon@zymecommunications.com
About The Native Antigen Company (https://thenativeantigencompany.com/ )
The Native Antigen Company (NAC) specialises in development and manufacture of native and recombinant viral and bacterial antigens. NAC’s antigens are used by pharmaceutical and in vitro diagnostic (IVD) manufacturers in vaccine research and serology, where correct folding and glycosylation are vital. The Company’s scientific know-how focuses on the isolation and purification of native antigens and the use of high-yielding mammalian cell expression systems which ensure conformity to native type.
As well as offering off-the-shelf antigens from a rapidly expanding portfolio, NAC develops and markets antibodies and undertakes bespoke product development and custom manufacture using its proprietary mammalian cell protein expression system. NAC’s new development and manufacturing facility is located near Oxford in the United Kingdom.
